Cardiovascular drug therapy for human newborn: review of pharmacodynamic data

Article (Supplemental Material)


This version is available from Sussex Research Online: http://sro.sussex.ac.uk/id/eprint/70339/

This document is made available in accordance with publisher policies and may differ from the published version or from the version of record. If you wish to cite this item you are advised to consult the publisher’s version. Please see the URL above for details on accessing the published version.

Copyright and reuse:
Sussex Research Online is a digital repository of the research output of the University.

Copyright and all moral rights to the version of the paper presented here belong to the individual author(s) and/or other copyright owners. To the extent reasonable and practicable, the material made available in SRO has been checked for eligibility before being made available.

Copies of full text items generally can be reproduced, displayed or performed and given to third parties in any format or medium for personal research or study, educational, or not-for-profit purposes without prior permission or charge, provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way.

http://sro.sussex.ac.uk
Inotropes are widely used in preterm and term infants with circulatory failure. Read about their pharmacodynamic effects in the article by Ergenekon et al.
1235 studies identified through database searching

1235 studies identified through database searching

790 excluded (Title and abstract)

445 studies for full assessment

344 did not meet inclusion criteria

101 studies selected for final assessment and discussion

AD(9), DOB(11), DA(28), HC(24), LS(4), MIL(4), NA(5), VAS(24), with repetitions

22 studies detected of level of evidence (LOE) I to IV
Rating System for the Hierarchy of Evidence
(LOE: Level of Evidence)

**LOE I:** Evidence from a systematic review or meta-analysis of all relevant RCTs

**LOE II:** Evidence obtained from well-designed RCTs

**LOE III:** Evidence obtained from well-designed controlled trials without randomization

**LOE IV:** Evidence from well-designed case-control and cohort studies

**LOE V:** Evidence from systematic reviews of descriptive and qualitative studies

**LOE VI:** Evidence from single descriptive or qualitative studies

**LOE VII:** Evidence from the opinion of authorities and/or reports of expert committees